On Tuesday, Atara Biotherapeutics Inc (NASDAQ: ATRA) opened lower -7.91% from the last session, before settling in for the closing price of $6.57. Price fluctuations for ATRA have ranged from $6.50 to $39.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 31.51%. Company’s average yearly earnings per share was noted 85.95% at the time writing. With a float of $4.31 million, this company’s outstanding shares have now reached $5.74 million.
Let’s determine the extent of company efficiency that accounts for 225 employees. In terms of profitability, gross margin is 82.7%, operating margin of -119.24%, and the pretax margin is -132.56%.
Atara Biotherapeutics Inc (ATRA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Atara Biotherapeutics Inc is 25.12%, while institutional ownership is 42.26%. The most recent insider transaction that took place on Nov 18 ’24, was worth 11,198. In this transaction EVP, Chief Regulatory Officer of this company sold 1,000 shares at a rate of $11.20, taking the stock ownership to the 19,378 shares. Before that another transaction happened on Nov 18 ’24, when Company’s EVP, CFO and COO sold 1,364 for $11.20, making the entire transaction worth $15,274. This insider now owns 23,392 shares in total.
Atara Biotherapeutics Inc (ATRA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 85.95% per share during the next fiscal year.
Atara Biotherapeutics Inc (NASDAQ: ATRA) Trading Performance Indicators
Check out the current performance indicators for Atara Biotherapeutics Inc (ATRA). In the past quarter, the stock posted a quick ratio of 0.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -25.66, a number that is poised to hit -2.36 in the next quarter and is forecasted to reach -6.51 in one year’s time.
Technical Analysis of Atara Biotherapeutics Inc (ATRA)
Looking closely at Atara Biotherapeutics Inc (NASDAQ: ATRA), its last 5-days average volume was 0.96 million, which is a jump from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 1.77%. Additionally, its Average True Range was 2.07.
During the past 100 days, Atara Biotherapeutics Inc’s (ATRA) raw stochastic average was set at 4.89%, which indicates a significant increase from 4.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 267.72% in the past 14 days, which was higher than the 147.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.17, while its 200-day Moving Average is $11.37. However, in the short run, Atara Biotherapeutics Inc’s stock first resistance to watch stands at $6.60. Second resistance stands at $7.15. The third major resistance level sits at $7.75. If the price goes on to break the first support level at $5.45, it is likely to go to the next support level at $4.85. Now, if the price goes above the second support level, the third support stands at $4.30.
Atara Biotherapeutics Inc (NASDAQ: ATRA) Key Stats
There are currently 5,760K shares outstanding in the company with a market cap of 34.85 million. Presently, the company’s annual sales total 8,570 K according to its annual income of -276,130 K. Last quarter, the company’s sales amounted to 40,190 K and its income totaled -21,910 K.
